Navigation Links
J. Greg Davis Appointed President & Chief Executive Officer of Tryton Medical, Inc.
Date:4/28/2008

RESEARCH TRIANGLE PARK, N.C., April 28 /PRNewswire/ -- Tryton Medical, Inc. announced today that it has appointed J. Greg Davis as President and Chief Executive Officer. Founded in 2003, Tryton Medical is the leading developer of stents that are designed to definitively treat bifurcation lesions.

Mr. Davis joins Tryton Medical after a successful 20-year career with Guidant and Eli Lilly & Company. Mr. Davis is an experienced medical device executive with broad global and functional experience in finance, manufacturing, sales and general management. Most recently he was president of Guidant, Japan with profit and loss responsibility for the company's $225 million cardiovascular business. Prior to his work in Japan, Mr. Davis managed Guidant's product portfolio in 13 Asian countries. Mr. Davis earned a BS in Mechanical Engineering from The University of Minnesota and an MBA from The University of Michigan.

"I am excited about this opportunity because I believe the Tryton Side-Branch Stent(TM) will redefine the standard of care for bifurcation lesions," said Mr. Davis. "Tryton's elegant design, ease-of-use and stellar clinical results are impressive. I look forward to implementing the company's aggressive European commercialization strategy and U.S. clinical trial plans."

"We are delighted to welcome Greg to Tryton Medical during this pivotal time in the company's development," said Dan Cole, Co-Founder and Board Member of Tryton and General Partner of Spray Venture Partners. "We believe his proven track record of growing successful businesses and achieving results will enable Tryton to capitalize on its leadership position in the industry."

"Greg's rich international experience and customer focus will be real assets as we launch the Side-Branch Stent(TM) across Europe," said Rick Anderson, Board Member of Tryton and Managing Director of PTV Sciences, and former Company Group Chairman, Cordis Corporation. "The Tryton 1 (First in Man) trial results and recent CE Mark approval have created strong interest and enthusiasm among the European physician community."

About Tryton Medical, Inc.

Tryton Medical, Inc. was founded in 2003 by Aaron V. Kaplan, M.D. (Associate Professor of Medicine at Dartmouth Medical School/Dartmouth- Hitchcock Medical Center) and Dan Cole to develop stents for the definitive treatment of bifurcation lesions. The company recently completed a $14 million round of financing, led by PTV Sciences and RiverVest Venture Partners. The Company will be headquartered in Research Triangle Park, NC. For more information on Tryton Medical contact J. Greg Davis, at gdavis@trytonmedical.com or visit http://www.trytonmedical.com.


'/>"/>
SOURCE Tryton Medical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. NCRA Urges U.S. Reps. Danny Davis and Judy Biggert to Approve in Conference the Higher Education Reauthorization Bill Providing Closed Captioning for 30 Million Deaf and Hard-of-Hearing Americans
2. Boston Kids Enjoy Free Davis Vision Screenings
3. Davis Vision, United Concordia Free Clinic Promotes Childrens Eye and Dental Health
4. TeamStaff Hires Jeff Davis as Director of Operations for Government Solutions Subsidiary
5. Sex & the City Gets Serious About HIV and AIDS in South Africa - Kristin Davis Helps Oxfam Break the Stigma and Close the Treatment Gaps Fuelling AIDS
6. Congressman Davis to Tour Pathology Laboratory, Learn Critical Role in Patient Care
7. New UC Davis study finds physician style and HMO affiliation impact lengths of patient visit
8. UC Davis researchers identify a cellular pathway that makes prostate cancer fatal
9. UC Davis researchers discover novel pathway to increased inflammation in diabetes patients
10. UC Davis researchers find evidence of mature heart cell potential in embryonic stem cells
11. After Dropping 162 Pounds, Jodi Davis Inspires Other Michigan Women to Get Moving and Lose Weight Through WalkyTalk.com(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... February 10, 2016 , ... LaserShip, a regional parcel carrier that services the ... Eastern Michigan last Friday in order to aid in the Flint water crisis. In ... a facility located in Clio, only 15 miles away from Flint. , “We have ...
(Date:2/10/2016)... ... February 10, 2016 , ... InDemand ... within Healthcare, recently partnered with Heart City Health Center to improve ... 23 years, Heart City Health Center has provided the Elkhart community with access ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... 10 ... Brand. There were three leading bottled water brand owners that topped the list as ... enhance connectivity and optimize conversion. The premier brand was Tibet 5100, a top notch ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... welcomes S.S. Nesbitt as the latest addition to its growing list of Partner ... locations throughout the Southeast, from Orlando to Huntsville and in between. , Harnessing ...
(Date:2/10/2016)... ... February 10, 2016 , ... Pediatric therapists are challenged to ... shows that the Goal Attainment Scale (GAS) captures 20% more change in outcomes ... more about the Goal Attainment Scale, Education Resources Inc. is offering a course ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... and PITTSBURGH, Feb. 10, 2016 Mylan N.V. (NASDAQ, ... quarter and year ended December 31, 2015. ... Full year adjusted total revenues of $9.45 billion, up ... year; GAAP total revenues of $9.43 billion. Excluding the ... markets specialty and branded generics business (the "EPD Business"), ...
(Date:2/10/2016)... , Feb. 10, 2016  Resolve Therapeutics, ... transformative new approaches to the treatment of lupus ... of a multiple ascending dose study in patients ... compound RSLV-132. --> ... placebo-controlled multiple ascending dose study of RSLV-132 in ...
(Date:2/10/2016)... , Feb. 10, 2016  Rich Pharmaceuticals, Inc. (OTC ... a 1-for-100 reverse split of its issued and outstanding ... trading on Thursday, February 11, 2016. The Company,s common ... CUSIP number 76303T308 and temporary ticker symbol "RCHAD". After ... under the ticker symbol (RCHA).  --> ...
Breaking Medicine Technology: